RETHYMIC 22000 mm/1
allogenic thymocyte-depleted thymus tissue-agdc · IMPLANT · Sumitomo Pharma America, Inc.
RETHYMIC is a implant containing allogenic thymocyte-depleted thymus tissue-agdc at 22000 mm/1, taken intramuscular. Manufactured by Sumitomo Pharma America, Inc..
Key Facts
- Brand Name
- RETHYMIC
- Generic Name
- allogenic thymocyte-depleted thymus tissue-agdc
- NDC Code (Product)
72359-001- Manufacturer
- Sumitomo Pharma America, Inc.
- Strength
- 22000 mm/1
- Dosage Form
- IMPLANT
- Route
- INTRAMUSCULAR
- Marketing Status
- Application #
- BLA125685
- Marketing Start
- 10/08/2021
Recall History
No Recall HistoryFrequently Asked Questions
What is RETHYMIC used for?
RETHYMIC contains allogenic thymocyte-depleted thymus tissue-agdc. It is a implant taken intramuscular. Consult your doctor for specific uses.
Is RETHYMIC a controlled substance?
RETHYMIC is not classified as a controlled substance by the DEA.
What is the generic name for RETHYMIC?
The generic name for RETHYMIC is allogenic thymocyte-depleted thymus tissue-agdc. There are no other listed brand versions of allogenic thymocyte-depleted thymus tissue-agdc.
What is the NDC code for RETHYMIC 22000 mm/1?
The NDC (National Drug Code) for RETHYMIC 22000 mm/1 is 72359-001, listed by Sumitomo Pharma America, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)